articleTop 1% cited

Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case–control study

European Journal of Endocrinology · 2013 · Vol. 169(4) · pp. 471–478

Katrien Wierckx✉(Ghent University Hospital)Els Elaut(Ghent University Hospital)Eugene Declercq(Ghent University Hospital)Gunter Heylens(Ghent University Hospital)Griet De Cuypere(Ghent University Hospital)Youri Taes(Ghent University Hospital)Jean‐Marc Kaufman(Ghent University Hospital)Guy T’Sjoen(Ghent University Hospital)

View via DOI Publisher page

Abstract

Morbidity rate during cross-sex hormone therapy was relatively low, especially in trans men. We observed a higher prevalence of venous thrombosis, myocardial infarction, CVD, and type 2 diabetes in trans women than in the control population. Morbidity rates in trans men and controls were similar, with the exception of the increased prevalence of type 2 diabetes.

LGBTQ Health, Identity, and PolicyMedicineHormone therapyInternal medicineDiabetes mellitusMyocardial infarctionAdverse effectVenous thrombosisPopulationCohortSex hormone-binding globulin

MeSH terms

AdultCardiovascular DiseasesCerebrovascular DisordersCross-Sectional StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedMorbidityMyocardial InfarctionNeoplasmsPulmonary EmbolismRisk FactorsGonadal Steroid Hormones

Citations

323

FWCI

16.72

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

References

Hormonal therapy and sex reassignment: a systematic review and meta‐analysis of quality of life and psychosocial outcomes